Miriam Cintron

UFDI investigators and collaborators found that granulocyte colony stimulating factor monotherapy did not affect C-peptide production, HbA1c, or insulin dose.This study supports the continued exploration of G-CSF and other mobilizing agents in subjects with T1D, but only when combined with immunodepleting agents where synergistic mechanisms of action have previously demonstrated…

UF and UF Health faculty, postdoctoral fellows, and graduate students submitted a record number of original research presentations for the American Diabetes Association’s 74th Scientific Sessions held June 13-17, 2014 at the Moscone Center in San Francisco, California. This year's submissions represent one of the largest showcases of research emanating from UF.

Diabetes investigators at UF Health are seeking participants for a pharmaceutical research study of 1 and up to 3 years to test an investigational new drug for the treatment of Type 1 diabetes. We are looking for males and females between the ages of 18 and 35 who have been diagnosed with Type 1 diabetes within the past 8 weeks. Enrolled participants will receive payment compensation for their time and travel during the study. Learn more.